A Phase 1 interventional study of Fenretinide and Placebo in Safety and Tolerability, sponsored by Island Pharmaceuticals. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Island Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial was to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions to answer were:
Participants will be asked to:
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.
This study is a randomized, double-blind, placebo-controlled single ascending dose study. There are 3 planned dose-level cohorts (Cohorts 1-3). Each dose-level cohort will consist of 8 subjects (6 active + 2 placebo), who will be treated under fasted conditions. The subjects in the highest tolerated dose-level cohort (determined by the Safety Review Committee) will also be administered ISLA101 or placebo under fed conditions, in a cross-over manner (Cohort 4).
Proposed doses are 300, 600, and 900 mg/m\^2 (equivalent to 8.1, 16.2, and 24.3 mg/kg). Each subject will be allocated to 1 dose level only.
The study will include a 5-day stay in the clinical research unit followed by a final safety follow-up visit at Day 8, where subjects will be under fasted conditions when they are dosed on Study Day 1.
For cohort 4, the study will again include a 5-day stay in the clinical research unit followed by a final safety follow-up visit at Day 17, where subjects will be under fed conditions when they are dosed on Study Day 10.
Island Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females not of childbearing potential, as defined in the following criteria:
i. Natural post-menopausal females with at least 12 months from natural spontaneous amenorrhea and a serum follicle-stimulating hormone (FSH) concentration ≥ 40 IU/L.
ii. Post-surgical females must have undergone bilateral oophorectomy at least 6 weeks prior to study.
Male subjects with female partners of childbearing potential must agree to practice abstinence or use a combination of 2 of the following acceptable methods during the study and for at least 90 days after dosing:
Exclusion Criteria:
Criteria at the discretion of the Investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of fenretinide, 300 mg/m\^2 under fasted conditions (Phase 1)
Drug: Fenretinide
Single oral dose of fenretinide, 600 mg/m\^2 under fasted conditions (Phase 1) Once all groups finish Phase 1, return to complete Phase 2 with a single oral dose of fenretinide, 600 mg/m\^2 under fed conditions per recommendation from the independent Safety Review Committee.
Drug: Fenretinide
Single oral dose of fenretinide, 900 mg/m\^2 under fasted conditions (Phase 1)
Drug: Fenretinide
Single oral dose of placebo capsules under fasted conditions (Phase 1) Once all groups finish Phase 1, return to complete Phase 2 with a single oral dose of placebo capsules under fed conditions per recommendation from the independent Safety Review Committee.
Drug: Placebo
Ascending single doses of oral fenretinide
Single oral dose of matching placebo capsules
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions
Time frame: First Intervention (Day 1 to Day 8)
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions
25 total subjects were enrolled in the study.
Time frame: First Intervention (Day 1 to Day 8)
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions
Subjects in the 600 mg/m\^2 came back to complete the fed cohort, as this was the only group to return based on the recommendations by the Safety Review Committee. Only 4 out of the 6 subjects returned for this cohort (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: Second Intervention (Day 9 to Day 17)
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: Second Intervention (Day 9 to 17)
Assess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide
Secondary objective
Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Assess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Assess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Assess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Assess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
| Milestone | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 7 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Milestone | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Started | 0 | 3 | 0 | 1 |
| Completed | 0 | 3 | 0 | 1 |
| Not completed | 0 | 0 | 0 | 0 |
| Participants | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions | 1 | 2 | 3 | 2 |
25 total subjects were enrolled in the study.
| Participants | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions | 0 | 0 | 0 | 0 |
Secondary objective
| ng/mL | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Fenretinide 600 mg/m^2 (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|
| Assess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide | 195.8 ± 92.35 | 524.8 ± 74.2 | 624.2 ± 142.2 | — | 1455 ± 521.6 | — |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| hours | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Fenretinide 600 mg/m^2 (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|
| Assess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State | 5.895 (2.97 to 6.0) | 5.15 (5.07 to 6.02) | 5.015 (4.88 to 6.0) | — | 5.98 (5.98 to 9.97) | — |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| h*ng/mL | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Fenretinide 600 mg/m^2 (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|
| Assess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State | 3479 ± 1947 | 8209 ± 836.9 | 9621 ± 2145 | — | 25800 ± 8726 | — |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| h*ng/mL | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Fenretinide 600 mg/m^2 (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|
| Assess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State | 3212 ± 1795 | 7894 ± 844.6 | 9089 ± 2039 | — | 24460 ± 8395 | — |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| hours | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Fenretinide 600 mg/m^2 (Fed) | Placebo (Fed) |
|---|---|---|---|---|---|---|
| Assess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State | 22.41 (9.788 to 35.73) | 28.21 (22.21 to 42.64) | 26.67 (21.23 to 29.47) | — | 27.77 (26.41 to 29.23) | — |
Subjects in the 600 mg/m\^2 came back to complete the fed cohort, as this was the only group to return based on the recommendations by the Safety Review Committee. Only 4 out of the 6 subjects returned for this cohort (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| Participants | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions | 0 | 0 | 0 | 0 |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| Participants | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo |
|---|---|---|---|---|
| Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions | 0 | 0 | 0 | 0 |
Collected over Subjects were monitored throughout the study for adverse reactions to the study drug and/or procedures from the time of informed consent through end of study (either through Day 8 for the fasted cohorts or through Day 17 for the fed cohort).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fenretinide 300 mg/m^2 (First Intervention) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Fenretinide 600 mg/m^2 (First Intervention) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Fenretinide 900 mg/m^2 (First Intervention) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Placebo (First Intervention) | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Fenretinide 600 mg/m^2 (Second Intervention) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Placebo (Second Intervention) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | Fenretinide 300 mg/m^2 (First Intervention) | Fenretinide 600 mg/m^2 (First Intervention) | Fenretinide 900 mg/m^2 (First Intervention) | Placebo (First Intervention) | Fenretinide 600 mg/m^2 (Second Intervention) | Placebo (Second Intervention) |
|---|---|---|---|---|---|---|
| diarrheaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 1/7 | 0/3 | 0/1 |
| neutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/6 | 0/7 | 0/3 | 0/1 |
| PhotophobiaEye disorders | 0/6 | 1/6 | 0/6 | 0/7 | 0/3 | 0/1 |
| vascular access site thrombosisGeneral disorders | 0/6 | 0/6 | 1/6 | 1/7 | 0/3 | 0/1 |
| musculoskeletal painMusculoskeletal and connective tissue disorders | 1/6 | 0/6 | 0/6 | 0/7 | 0/3 | 0/1 |
| lethargyNervous system disorders | 0/6 | 0/6 | 1/6 | 0/7 | 0/3 | 0/1 |
| dry skinSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 | 0/7 | 0/3 | 0/1 |
| Haematoma muscleInjury, poisoning and procedural complications | 0/6 | 0/6 | 1/6 | 0/7 | 0/3 | 0/1 |
25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).
| Age, Continuous(years) | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 32.57 ± 10.443 | 40.23 ± 9.438 | 34.33 ± 13.049 | 30.66 ± 10.588 | 34.3 ± 10.872 |
| Sex: Female, Male(Participants) | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 0 | 0 | 2 |
| Male | 5 | 5 | 6 | 7 | 23 |
| Race (NIH/OMB)(Participants) | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 3 | 3 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 1 | 3 | 4 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 0 | 1 | 3 |
| Region of Enrollment(participants) | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Total |
|---|---|---|---|---|---|
| Australia | 6 | 6 | 6 | 7 | 25 |
| Body Mass Index(kg/m^2) | Fenretinide 300 mg/m^2 | Fenretinide 600 mg/m^2 | Fenretinide 900 mg/m^2 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 24.9 ± 4.35 | 26.3 ± 4.40 | 22.78 ± 2.79 | 24.31 ± 3.12 | 24.56 ± 3.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Feb 2024, 2 months.
Results were first posted in Jan 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenretinide
Island Pharmaceuticals